# Electrophysiological Biomarkers of AV-101

> **NCT03583554** · PHASE1,PHASE2 · COMPLETED · sponsor: **Marijn Lijffijt, PhD** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Placebo
- **DRUG:** AV-101 720 mg
- **DRUG:** AV-101 1440 mg

## Key facts

- **NCT ID:** NCT03583554
- **Lead sponsor:** Marijn Lijffijt, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-01
- **Primary completion:** 2019-10-19
- **Final completion:** 2019-10-19
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03583554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03583554, "Electrophysiological Biomarkers of AV-101". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03583554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*